Pharmafile Logo
Pharmafocus logo
Advanced Search

Regeneron

Showing 15 posts of 105 posts found.

ipos0_l

Regeneron and Teva’s experimental drug halted by FDA clinical hold

October 17, 2016
Manufacturing and Production Regeneron, Teva, back pain, osteoarthritis

Regeneron Pharmaceuticals and Teva Pharmaceuticals had only just agreed a deal worth a potential $2.6 billion to co-develop Regeneron’s fasinumab …

News
eylea-product-box-md

Regeneron’s Eylea fails combination study endpoint

October 3, 2016
Research and Development, Sales and Marketing Eylea, Regeneron

Regeneron has announced that its eye drug Eylea (aflibercept) failed its primary endpoint in a mid-stage trial investigating its effectiveness …

News
shutterstock_273326141

Teva and Regeneron team up for $2.6 billion pain treatment development

September 21, 2016
Research and Development, Sales and Marketing Regeneron, Teva, fasinumab, osteoarthritis

Teva and Regeneron have entered an agreement worth up to $2.6 billion to develop and market the latter’s experimental nerve …

News
clinical_trial-web

Sanofi & Regeneron’s Praluent cholesterol treatment smashes Phase III target

August 30, 2016
Manufacturing and Production, Research and Development Regeneron, Sanofi, apheresis, cholesterol, phase III

Sanofi and Regeneron have announced that their Praluent injection generated positive Phase III results investigating patients with an inherited form …

News
praluent_75mg_pen_box_hr

Amgen, Sanofi cholesterol medicines “not cost-effective”, need to drop price by two-thirds

August 17, 2016
Research and Development, Sales and Marketing Amgen, QALY, Regeneron, Repatha, Sanofi, cost effective, cost-effective, praluent

A new study published in JAMA has suggested that Amgen, Sanofi and Regeneron would have to reduce their prices for …

News
regeneron

Eylea sales jump helps boost Regeneron in Q2 results

August 5, 2016
Medical Communications, Research and Development 2016, Eylea, Q2, Regeneron, results

Regeneron Pharmaceuticals has published positive Q2 results with a 27% rise in Eylea (aflibercept) sales in the US helping to …

News
a_scientist_at_work_at_sanofis_immunology_laboratory_in_thailand

EMA accepts MMA for rheumatoid arthritis treatment Sarilumab

August 1, 2016
Research and Development, Sales and Marketing EMA, MAA, Regeneron, Sanofi, sarilumab

Sanofi and Regeneron Pharmaceuticals have announced that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) for …

News

Sanofi, Regeneron say cholesterol drug Praluent approved in Japan

July 5, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Japan, Regeneron, Sanofi, cardiovascular, cholestrol, praleunt

Sanofi (Euronext: SAN) and Regeneron Pharmaceuticals (Nasdaq: REGN) said the lawmakers in Japan have granted marketing and manufacturing authorization for …

News
sample

Sanofi and Regeneron combo shows superiority in late-stage atopic dermatitis trials

June 6, 2016
Research and Development, Sales and Marketing Dupilumab, Regeneron, Sanofi, atopic dermatitis, late stage trials

Sanofi (NYSE: SNY) and Regeneron (NASDAQ: REGN) have announced positive results from a Phase III trial evaluating dupilumab in patients …

News
novartis_window

Research shows Novartis’s Entresto reduces cardiovascular death and heart failure

April 4, 2016
Research and Development, Sales and Marketing Entresto, Novartis, Regeneron, Sanofi, cardiovascular, clinical trial, patent

Novartis has announced results from the PARADIGM-HF clinical trial that show that Entresto (sacubitril/valsartan) consistently demonstrated benefit among heart failure …

News

Sanofi and Regeneron announce positive Phase III trial results for chronic skin disease treatment

April 1, 2016
Medical Communications, Research and Development Dupilumab, Regeneron, Sanofi, atopic dermatitis, phase III, skin disease

Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals (NASDAQ: REGN) have announced positive top line results for dupilumab in Phase III clinical …

News
sanofi_pasteur_scientist

Sanofi and Regeneron meet endpoint in Phase III Praluent study

March 23, 2016
Research and Development Regeneron, Sanofi, endpoint, escape, hefh, odyssey, phase 3, phase III, positive, praulent, trial

Sanofi and Regeneron Pharmaceuticals have announced that their Phase III ODYSSEY ESCAPE clinical trial evaluating Praluent (alirocumab) met its primary …

News
amgen_sign_on_wall

Amgen wins high-profile cholesterol drug patent case v Sanofi

March 17, 2016
Sales and Marketing Amgen, PCSK9, Regeneron, Repatha, Sanofi, cholesterol, praluent

A Delaware district court jury has ruled in favour of Amgen in an ongoing dispute around patents for cholesterol-lowering drugs …

News
sanofi_logo_on_building

Sanofi says its RA drug bested Humira in Phase III study

March 11, 2016
Medical Communications, Research and Development Humira, Regeneron, Sanofi

Sanofi and its R&D arm Regeneron Pharmaceuticals say their monoclonal antibody sarilumab outperformed AbbVie’s Humira in treating the symptoms of …

News
nice

NICE rejects cholesterol drug Praluent in draft guidance

February 8, 2016
Research and Development, Sales and Marketing NICE, Regeneron, Sanofi, cholesterol

NICE has published draft guidance not recommending Sanofi/Regeneron’s Praluent (alirocumab) as an option for people with high cholesterol (primary hypercholesterolaemia …

News
The Gateway to Local Adoption Series

Latest content

Teva announces positive results from trial of AJOVY for migraine

December 5, 2025

Vetter announces leadership transition as Thomas Otto retires

December 5, 2025

Samsung Bioepis announces launch of two new denosumab biosimilars in Europe

December 4, 2025

Medicus Pharma appoints Carolyn Bonner as CFO

December 4, 2025

Sandoz launches two new bone disease biosimilars in Europe

December 3, 2025